Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TF42
UPID:
UBS3B_HUMAN
Alternative names:
Cbl-interacting protein p70; Suppressor of T-cell receptor signaling 1; T-cell ubiquitin ligand 2; Tyrosine-protein phosphatase STS1/TULA2
Alternative UPACC:
Q8TF42; Q53GT5; Q53GT8; Q8NBV7; Q96IG9; Q96NZ2
Background:
Ubiquitin-associated and SH3 domain-containing protein B, also known as Cbl-interacting protein p70, plays a crucial role in cellular signaling. It interferes with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases, leading to the accumulation of activated receptors like EGFR on the cell surface. Its activity extends to tyrosine phosphatase towards substrates such as EGFR, FAK, SYK, and ZAP70, and it down-regulates proteins modified by tyrosine phosphorylation and ubiquitination.
Therapeutic significance:
Understanding the role of Ubiquitin-associated and SH3 domain-containing protein B could open doors to potential therapeutic strategies.